We further compared the expression of NRPs and PLXNs among the five breast cancer molecular subtypes, i.e., basal-like (Basal), Her2 enriched (Her2), luminal A (LumA), luminal B (LumB), and Normal like (Normal), where patients characterized into Basal and Her2 subtype have the least favorable survival. This evidence concerns the gene ERBB2 and breast carcinoma.